

(FILE 'HOME' ENTERED AT 16:33:26 ON 03 JUL 2002)

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO' ENTERED AT 16:33:41 ON 03 JUL 2002

L1 2 S CHERWONOGRODZKY
L2 3 S CHERWONOGRODZKY, JOHN/AU
L3 34291 S ALTERNARIA
L4 4865 S L3 AND CULTURE
L5 390 S L4 AND SUPERNATANT
L6 383 DUP REM L5 (7 DUPLICATES REMOVED)
L7 81 S L6 AND ELISA
L8 16 S L7 AND (CROSSREACTIVITY OR CROSS-REACTIVITY)

FILE 'STNGUIDE' ENTERED AT 16:41:19 ON 03 JUL 2002

L9 0 S CHAETOMIUM
L10 0 S FUSARIUM
L11 0 S ASPERGILLUS

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO' ENTERED AT 16:44:10 ON 03 JUL 2002

L12 5971 S CHAETOMIUM
L13 1404 S L12 AND CULTURE
L14 134 S L13 AND SUPERNATANT
L15 128 DUP REM L14 (6 DUPLICATES REMOVED)
L16 12 S L15 AND ELISA

FILE 'STNGUIDE' ENTERED AT 16:47:07 ON 03 JUL 2002

FILE 'CAPLUS, USPATFULL' ENTERED AT 16:49:58 ON 03 JUL 2002

FILE 'STNGUIDE' ENTERED AT 16:50:03 ON 03 JUL 2002

FILE 'BIOSIS, CABA, CAPLUS, EMBASE, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, JAPIO' ENTERED AT 16:50:21 ON 03 JUL 2002

L17 579656 S HIS
L18 94490 S FUSARIUM
L19 16532 S L18 AND CULTURE
L20 1237 S L19 AND SUPERNATANT
L21 174 S L20 AND ELISA
L22 55 S L21 AND (CROSSREACTIV? OR CROSS-REACTIV?)
L23 55 DUP REM L22 (0 DUPLICATES REMOVED)
L24 177956 S ASPERGILLUS
L25 34805 S L24 AND CULTURE
L26 3989 S L25 AND SUPERNATANT
L27 1065 S L26 AND ELISA
L28 234 S L27 AND (CROSS-REACTIV? OR CROSSREACTIV?)
L29 233 DUP REM L28 (1 DUPLICATE REMOVED)
L30 4341 S BIPOLARIS
L31 1112 S L30 AND CULTURE
L32 86 S L31 AND SUPERNATANT
L33 48 S L32 AND ELISA
L34 14 S L33 AND (CROSS-REACTIV? OR CROSSREACTIV?)

=>

L2 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AB Liposome encapsulated antibiotic therapy has limited application against infectious organisms, which can sequester in non-phagocytic cells. Virulence factors of these infectious organisms, for example bacterial components, when used in the formulation of liposomes can enhance the effectiveness of liposomes as delivery systems in the treatment of disease. In this manner, multi-functional liposomes can be developed to treat target diseases. In addition to serving as antibiotic delivery systems, such liposomes also have an immunization effect. Thus, the liposomes can be used for both the prevention and treatment of diseases.
 AN 2001:468598 BIOSIS
 DN PREV200100468598
 TI Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents.
 AU **Cherwonogrodzky, John (1)**; Wong, Jonathan P.; Dininno, Vincent L.
 CS (1) Medicine Hat Canada
 ASSIGNEE: Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence, Ottawa, Canada
 PI US 6221386 April 24, 2001
 SO Official Gazette of the United States Patent and Trademark Office Patents, (Apr. 24, 2001) Vol. 1245, No. 4, pp. No Pagination. e-file. ISSN: 0098-1133.
 DT Patent
 LA English

L2 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS
 AB Liposome-encapsulated antibiotic therapy has limited application against infectious organisms, which can sequester in non-phagocytic cells. Virulence factors of these infectious organisms, for example bacterial polysaccharides, when used in the formulation of liposomes can enhance the effectiveness of liposomes as delivery systems in the treatment of disease. In this manner, multi-functional liposomes can be developed to treat target diseases. In addn. to serving as antibiotic delivery systems, such liposomes also have an immunization effect. Thus, the liposomes can be used for both the prevention and treatment of diseases. For example, an 8.5% increase in uptake by Vero tissue culture of ciprofloxacin encapsulated in liposomes contg. Brucella abortus polysaccharides was obsd. compared to control. Uptake of liposomes with B. melitensis lipopolysaccharides (LPS) was comparable to std. liposomes, indicating that B. melitensis LPS did not affect the invasiveness of the liposomes in Vero tissue culture, nor did it prevent entry of liposomes into this tissue culture.
 AN 2001:294884 CAPLUS
 DN 134:300824
 TI Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents
 IN **Cherwonogrodzky, John**; Wong, Jonathan P.; Dininno, Vincent L.
 PA Canada, Minister of National Defence, Can.
 SO U.S., 8 pp., Cont.-in-part of U.S. Ser. No. 782,129, abandoned. CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6221386	B1	20010424	US 1999-251304	19990217
	CA 2171369	AA	19970909	CA 1996-2171369	19960308
PRAI	CA 1996-2171369	A	19960308		
	US 1997-782129	B2	19970113		

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 3 USPATFULL

AB Liposome encapsulated antibiotic therapy has limited application against infectious organisms, which can sequester in non-phagocytic cells. Virulence factors of these infectious organisms, for example bacterial components, when used in the formulation of liposomes can enhance the effectiveness of liposomes as delivery systems in the treatment of disease. In this manner, multi-functional liposomes can be developed to treat target diseases. In addition to serving as antibiotic delivery systems, such liposomes also have an immunization effect. Thus, the liposomes can be used for both the prevention and treatment of diseases.

AN 2001:59409 USPATFULL

TI Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents

IN **Cherwonogrodzky, John**, Medicine Hat, Canada
Wong, Jonathan P., Medicine Hat, Canada
Dininno, Vincent L., Radcliff, Canada

PA Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence, Ottawa, Canada (non-U.S. corporation)

PI US 6221386 B1 20010424

AI US 1999-251304 19990217 (9)

RLI Continuation-in-part of Ser. No. US 1997-782129, filed on 13 Jan 1997, now abandoned

PRAI CA 1996-2171369 19960308

DT Utility

FS Granted

EXNAM Primary Examiner: Kishore, Gollamudi S.

LREP Nixon & Vanderhye P.C.

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 775

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s alternaria

L3 34291 ALTERNARIA

=> s 13 and culture

L4 4865 L3 AND CULTURE

=> s 14 and supernatant

L5 390 L4 AND SUPERNATANT

=> dup rem 15

PROCESSING COMPLETED FOR L5

L6 383 DUP REM L5 (7 DUPLICATES REMOVED)

=> s 16 and ELISA

5 FILES SEARCHED...

L7 81 L6 AND ELISA

=> s 17 and (crossreactivity or cross-reactivity)

L8 16 L7 AND (CROSSREACTIVITY OR CROSS-REACTIVITY)

=> d ab bib 18

L8 ANSWER 1 OF 16 USPATFULL

AB The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.

AN 2002:141109 USPATFULL
 TI Death domain containing receptor 5
 IN Ni, Jian, Rockville, MD, UNITED STATES
 Gentz, Reiner L., Rockville, MD, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Rosen, Craig A., Laytonville, MD, UNITED STATES
 PA Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)
 PI US 2002072091 A1 20020613
 AI US 2001-874138 A1 20010606 (9)
 RLI Continuation of Ser. No. US 2000-565009, filed on 4 May 2000, PENDING
 Continuation of Ser. No. US 1998-42583, filed on 17 Mar 1998, PENDING
 PRAI US 1999-148939P 19990813 (60)
 US 1999-133238P 19990507 (60)
 US 1999-132498P 19990504 (60)
 US 1997-40846P 19970317 (60)
 US 1997-54021P 19970729 (60)
 DT Utility
 FS APPLICATION
 LREP STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W.,
 SUITE 600, WASHINGTON, DC, 20005-3934
 CLMN Number of Claims: 97
 ECL Exemplary Claim: 1
 DRWN 7 Drawing Page(s)
 LN.CNT 8943
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ab bib 18 1-16

L8 ANSWER 1 OF 16 USPATFULL
 AB The present invention relates to novel Death Domain Containing
 Receptor-5 (DR5) proteins which are members of the tumor necrosis factor
 (TNF) receptor family, and have now been shown to bind TRAIL. In
 particular, isolated nucleic acid molecules are provided encoding the
 human DR5 proteins, DR5 polypeptides are also provided as are vectors,
 host cells and recombinant methods for producing the same. The invention
 further relates to screening methods for identifying antagonists and
 antagonists of DR5 activity.
 AN 2002:141109 USPATFULL
 TI Death domain containing receptor 5
 IN Ni, Jian, Rockville, MD, UNITED STATES
 Gentz, Reiner L., Rockville, MD, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Rosen, Craig A., Laytonville, MD, UNITED STATES
 PA Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)
 PI US 2002072091 A1 20020613
 AI US 2001-874138 A1 20010606 (9)
 RLI Continuation of Ser. No. US 2000-565009, filed on 4 May 2000, PENDING
 Continuation of Ser. No. US 1998-42583, filed on 17 Mar 1998, PENDING
 PRAI US 1999-148939P 19990813 (60)
 US 1999-133238P 19990507 (60)
 US 1999-132498P 19990504 (60)
 US 1997-40846P 19970317 (60)
 US 1997-54021P 19970729 (60)
 DT Utility
 FS APPLICATION
 LREP STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W.,
 SUITE 600, WASHINGTON, DC, 20005-3934
 CLMN Number of Claims: 97
 ECL Exemplary Claim: 1
 DRWN 7 Drawing Page(s)
 LN.CNT 8943
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 16 USPATFULL

AB The invention provides isolated nucleic acid and amino acid sequences of A. fumigatus profilin, methods of screening for A. fumigatus profilin modulators using biologically active A. fumigatus profilin, and kits for screening for A. fumigatus profilin modulators.

AN 2002:136816 USPATFULL

TI Aspergillus fumigatus profilin

IN Nislow, Corey E., San Francisco, CA, United States

Wong, Kee, San Francisco, CA, United States

PA Cytokinetics, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 6403372 B1 20020611

AI US 2000-722946 20001127 (9)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Duffy, Patricia A.

LREP Townsend and Townsend and Crew LLP

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 3 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1703

L8 ANSWER 3 OF 16 USPATFULL

AB There can be provided a fungal antigen which is an insoluble fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed; a process for producing the same; a nucleic acid encoding the fungal antigen; a biologic product containing the fungal antigen; a method of stimulating immunological responses by using the biologic product; a method of suppressing allergic reaction to fungi in a vertebrate; and a method for diagnosing a disease caused by fungi in a vertebrate.

AN 2002:112558 USPATFULL

TI Fungal antigens and process for producing the same

IN Takesako, Kazutoh, Otsu-shi, JAPAN

Mizutani, Shigetoshi, Gamo-gun, JAPAN

Endo, Masahiro, Kusatsu-shi, JAPAN

Kato, Ikunoshin, Uji-shi, JAPAN

PA TAKARA SHUZO CO., LTD, Kyoto, JAPAN (non-U.S. corporation)

PI US 2002058293 A1 20020516

AI US 2001-987190 A1 20011113 (9)

RLI Division of Ser. No. US 1999-262856, filed on 4 Mar 1999, PENDING

PRAI WO 1997-JP3041 19970829

JP 1996-255400 19960904

JP 1997-99775 19970331

DT Utility

FS APPLICATION

LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 3093

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 16 USPATFULL

AB The present invention includes a method to detect IgE using a human Fc epsilon receptor (Fc.sub..epsilon.R) to detect IgE antibodies in a biological sample from a cat, a dog, or a horse. The present invention also relates to kits to perform such methods.

AN 2002:60937 USPATFULL

TI Method to detect IgE

IN Frank, Glenn R., Wellington, CO, UNITED STATES

Porter, James P., Fort Collins, CO, UNITED STATES

Rushlow, Keith E., Fort Collins, CO, UNITED STATES

Wassom, Donald L., Fort Collins, CO, UNITED STATES

PI US 2002034771 A1 20020321
AI US 2001-944277 A1 20010830 (9)
RLI Division of Ser. No. US 1999-285873, filed on 31 Mar 1999, GRANTED, Pat.
No. US 6309832 Division of Ser. No. US 1996-756387, filed on 26 Nov
1996, GRANTED, Pat. No. US 5945294
DT Utility
FS APPLICATION
LREP Heska Corporation, Intellectual Property Dept., 1613 Prospect Parkway,
Fort Collins, CO, 80525
CLMN Number of Claims: 105
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 2278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 16 USPATFULL

AB A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one or more pharmaceutically acceptable excipients. The composition may be used topically as a solution, dispersion, powder or in the form of microspheres. The polyclonal antibody is preferably a recombinant polyclonal antibody produced by phage display technology. The pairing of specific immunoglobulin variable region light chain and heavy chain maintained from the original polyclonal immune response or selected by panning using the allergen in question is preferably maintained by bulk transfer of the pairs into an expression vector. The allergen may be an allergen of house dust mites, e.g. *Dermatophagoides farinae* or *D. pteronyssinus*; dander from cat, dog or horse; tree pollen, e.g. pollen from birch (*Betula alba*), alder, hazel, oak, willow, plane, beech, elm, maple, ash and hornbeam; grass pollen, e.g. pollen from timothy grass (*Phleum pratense*), bluegrass (*Poa pratense*), rye grass (*Lolium perenne*), Orchard grass (*Dactylis glomerata*), ragweed (*Ambrosia artemisiifolia*), sweet vernal grass (*anthoxanthum odoratum*), and rye (*Secale cereale*); or fungi (e.g. **Alternaria**, *Aspergillus*, *Cladosporium* and *Penicillium*).

AN 2002:16577 USPATFULL

TI Polyclonal antibody composition for treating allergy

IN Haurum, John S., Copenhagen O, DENMARK

Drejer, Kirsten, Vaerloose, DENMARK

Morch, Ulrik Gregers Winther, Copenhagen K, DENMARK

PA Symphogen A/S (non-U.S. corporation)

PI US 2002009453 A1 20020124

AI US 2001-866573 A1 20010525 (9)

PRAI US 2000-211981P 20000616 (60)

DT Utility

FS APPLICATION

LREP DARBY & DARBY, 805 THIRD AVENUE, 27TH FLR., NEW YORK, NY, 10022

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1173

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 16 USPATFULL

AB There can be provided a fungal antigen which is an insoluble fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed; a process for producing the same; a nucleic acid encoding the fungal antigen; a biologic product containing the fungal antigen; a method of stimulating immunological responses by using the biologic product; a method of suppressing allergic reaction to fungi in a vertebrate; and a method for diagnosing a disease caused by fungi in a vertebrate.

AN 2001:235097 USPATFULL
TI Fungal antigens and process for producing the same
IN Takesako, Kazutoh, Otsu, Japan
Mizutani, Shigetoshi, Gamo-gun, Japan
Endo, Masahiro, Kusatsu, Japan
Kato, Ikunoshin, Uji, Japan
PA Takara Shuzo Co., Ltd., Kyoto, Japan (non-U.S. corporation)
PI US 6333164 B1 20011225
AI US 1999-262856 19990304 (9)
RLI Continuation-in-part of Ser. No. WO 1997-JP3041, filed on 29 Aug 1997
PRAI JP 1996-255400 19960904
JP 1997-99775 19970331
DT Utility
FS GRANTED
EXNAM Primary Examiner: Smith, Lynette R. F.; Assistant Examiner: Baskar,
Padma
LREP Birch, Stewart, Kolasch & Birch, LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2782
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 16 USPATFULL

AB The present invention includes a method to detect IgE using a human Fc
epsilon receptor (Fc.sub..epsilon. R) to detect IgE antibodies in a
biological sample from a cat, a dog, or a horse. The present invention
also relates to kits to perform such methods.
AN 2001:190910 USPATFULL
TI Method to detect IgE
IN Frank, Glenn R., Wellington, CO, United States
Porter, James P., Fort Collins, CO, United States
Rushlow, Keith E., Fort Collins, CO, United States
Wassom, Donald L., Fort Collins, CO, United States
PA Heska Corporation, Fort Collins, CO, United States (U.S. corporation)
PI US 6309832 B1 20011030
AI US 1999-285873 19990331 (9)
RLI Division of Ser. No. US 1996-756387, filed on 26 Nov 1996, now patented,
Pat. No. US 5945294
DT Utility
FS GRANTED
EXNAM Primary Examiner: Swartz, Rodney P.
LREP Heska Corporation
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 16 USPATFULL

AB The present invention relates to parasitic nematode transglutaminase
proteins; to parasitic nematode transglutaminase nucleic acid molecules,
including those that encode such transglutaminase proteins; to
antibodies raised against such transglutaminase proteins; and to
compounds that inhibit parasitic nematode transglutaminase activity. The
present invention also includes methods to obtain such proteins, nucleic
acid molecules, antibodies, and inhibitory compounds. Also included in
the present invention are therapeutic compositions comprising such
proteins, nucleic acid molecules, antibodies and/or inhibitory compounds
as well as the use of such therapeutic compositions to protect animals
from diseases caused by parasitic nematodes. This invention also relates
to the surprising discovery that parasitic nematode transglutaminase
proteins have protein disulfide isomerase activity. Accordingly, this
invention relates further to inhibitors of the protein disulfide

isomerase activity of said transglutaminases.
AN 2001:190730 USPATFULL
TI Parasitic nematode transglutaminase proteins and uses thereof
IN Chandrashekar, Ramaswamy, Fort Collins, CO, United States
Mehta, Kapil, Houston, TX, United States
PA Heska Corporation, Fort Collins, CO, United States (U.S. corporation)
The Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6309644 B1 20011030
AI US 1997-874102 19970612 (8)
RLI Continuation-in-part of Ser. No. US 1996-781420, filed on 3 Dec 1996, now patented, Pat. No. US 6248872
DT Utility
FS GRANTED
EXNAM Primary Examiner: Navarro, Mark
LREP Heska Corporation
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 16 USPATFULL

AB Two chitinses from Trichoderma harzianum P1 (ATCC 74058) show chitin-containing-fungus-inhibiting activity. One is an endochitinase and the other is a chitobiase. Both have molecular weights of 40 kDa and isoelectric points of 3.9. A .lambda.gtl1 recombinant encoding for the endochitinase has been prepared (ATCC 55338) and the gene encoding for the endochitinase has been removed from the DNA of the recombinant by the restriction enzyme, Not I. Endochitinases and chitobiases including the two purified from Trichoderma harzianum strain P1 demonstrate synergy with each other in anti-fungal effect.

AN 2001:97415 USPATFULL
TI Purified chitinases and use thereof
IN Harman, Gary E., Geneva, NY, United States
Broadway, Roxanne M., Geneva, NY, United States
Tronsmo, Arne, Aas, Norway
Lorito, Matteo, Geneva, NY, United States
Hayes, Christopher K., Geneva, NY, United States
Di Pietro, Antonio, Binningen, Switzerland
PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)
PI US 6251390 B1 20010626
AI US 1992-919784 19920727 (7)
RLI Continuation-in-part of Ser. No. US 1991-716134, filed on 17 Jun 1991, now patented, Pat. No. US 5173419
DT Utility
FS GRANTED
EXNAM Primary Examiner: Prouty, Rebecca E.
LREP Nixon Peabody LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 1159
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 16 USPATFULL

AB Two chitinses from Trichoderma harzianum P1 (ATCC 74058) show chitin-containing-fungus-inhibiting activity. One is an endochitinase and the other is a chitobiase. Both have molecular weights of 40 kDa and isoelectric points of 3.9. Endochitinases and chitobiases including the two purified from Trichoderma harzianum strain P1 demonstrate synergy with each other in antifungal effect. Isolated gene encoding for the endochitinase has the sequence set forth in the Sequence Listing as SEQ

ID NO:1.
AN 2000:13003 USPATFULL
TI Gene encoding endochitinase
IN Harman, Gary E., Geneva, NY, United States
Tronsmo, Arne, Aas, Norway
Hayes, Christopher K., Geneva, NY, United States
Lorito, Matteo, Salerno, Italy
Klemsdahl, Sonja, .ANG.s, Norway
PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S.
corporation)
PI US 6020540 20000201
AI US 1994-371680 19941221 (8)
RLI Continuation-in-part of Ser. No. US 1993-45269, filed on 14 Apr 1993,
now patented, Pat. No. US 5378821 And Ser. No. US 1994-184115, filed on
21 Jan 1994, now abandoned , said Ser. No. US 45269 which is a
continuation-in-part of Ser. No. US 1992-919784, filed on 27 Jul 1992
which is a continuation-in-part of Ser. No. US 1991-716134, filed on 17
Jun 1991, now patented, Pat. No. US 5173419 , said Ser. No. US 184115
which is a continuation-in-part of Ser. No. US 1993-49390, filed on 21
Apr 1993, now patented, Pat. No. US 5474926 which is a
continuation-in-part of Ser. No. US 1992-990609, filed on 15 Dec 1992,
now patented, Pat. No. US 5326561
DT Utility
FS Granted
EXNAM Primary Examiner: Prouty, Rebecca E.
LREP Nixon, Hargrave, Devans & Doyle LLP
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 1939
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 16 USPATFULL
AB The present invention includes a method to detect IgE using a human Fc
epsilon receptor (Fc.sub..epsilon. R) to detect IgE antibodies in a
biological sample from a cat, a dog, or a horse. The present invention
also relates to kits to perform such methods.
AN 1999:102683 USPATFULL
TI Method to detect IgE
IN Frank, Glenn R., Wellington, CO, United States
Porter, James P., Fort Collins, CO, United States
Rushlow, Keith E., Fort Collins, CO, United States
Wassom, Donald L., Fort Collins, CO, United States
PA Heska Corporation, Fort Collins, CO, United States (U.S. corporation)
PI US 5945294 19990831
AI US 1996-756387 19961126 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Housel, James; Assistant Examiner: Swartz, Rodney P.
LREP Heska Corporation
CLMN Number of Claims: 77
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 16 USPATFULL
AB Monoclonal antibodies (MAbs) useful in the serological detection and
identification of rice blast were produced by hybridoma cells formed
from fusions of myeloma cells with splenocytes from BALB/c mice
immunized with an extract of a liquid **culture** fluid of an
isolate of Pyricularia grisea race IB-49. These MAbs reacted similarly
with the antigens in various serological techniques used, and did not
cross react with any unrelated fungal isolates representing 11 genera,

but reacted positively with all 20 races or isolates of *P. grisea*. The MABs could detect homologous antigen at about 60 ng fungal protein/ml and a 5-fold dilution of the extracts of infected rice tissue by **ELISA**. In accordance with another embodiment of the present invention, hybridoma lines secreting antibodies positive for the immunogen and negative for healthy rice tissue were selected from three independent fusions of NS-1 myeloma cells with splenocytes from mice immunized with crushed conidial suspensions of *P. grisea* race IB-49. MABs secreted from cell line 4G11, deposited with ATCC as HB11178, reacted strongly with conidial antigen. In cross-reaction tests with **ELISA**, MAb 4G11 reacted negatively with isolates representing 11 fungal genera and reacted positively with 11 and 12 isolates of *P. grisea* in **ELISA** and IFA, respectively. MAb 4G11 could detect homologous conidial antigen at 14-70 ng/ml, 10-20 conidia/well, and the fungal antigen in infected rice tissue in **ELISA**.

AN 1998:91814 USPATFULL
TI Serological detection and identification of rice blast
IN Lee, Fleet N., Stuttgart, AR, United States
Scott, Howard A., Fayetteville, AR, United States
Xia, Jun Q., Fayetteville, AR, United States
PA University of Arkansas, Little Rock, AK, United States (U.S. corporation)
PI US 5789183 19980804
AI US 1993-71573 19930601 (8)
RLI Continuation of Ser. No. US 1992-930239, filed on 14 Aug 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Grun, James L.
LREP Alexander, Daniel R. Head, Johnson & Kachigian
CLMN Number of Claims: 12
ECL Exemplary Claim: 1,4
DRWN 19 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1649
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 16 USPATFULL
AB The invention relates to monoclonal antibodies that react specifically with members of the genus *Mycosphaerella* and hybridomas that produce such antibodies. The invention is further directed to a method for making a hybridoma cell line that produces monoclonal antibodies that react specifically with at least one species of *Mycosphaerella*, and a method of obtaining monoclonal antibodies therefrom. Methods and kits for diagnosing *Mycosphaerella* infections in plant material using such monoclonal antibodies are also within the scope of the invention.
AN 96:87487 USPATFULL
TI Monoclonal antibodies to *mycosphaerella* species
IN Petersen, Frank P., Burlington, NJ, United States
Clymer, Mark D., Norristown, PA, United States
Miller, Sally A., Pennsauken, NJ, United States
Rittenburg, James H., Perkasio, PA, United States
Grothaus, G. David, Burlington, NJ, United States
PA Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)
PI US 5558997 19960924
AI US 1994-311813 19940926 (8)
RLI Continuation of Ser. No. US 1992-955400, filed on 1 Oct 1992, now abandoned which is a continuation of Ser. No. US 1990-546341, filed on 29 Jun 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Knodel, Marian C.; Assistant Examiner: Duffy, Patricia A.
LREP Elmer, James Scott
CLMN Number of Claims: 33

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1460

L8 ANSWER 14 OF 16 USPATFULL

AB This invention is directed to methods for the enhanced production and recovery of taxol and taxanes by cell **cultures** of Taxus species.

AN 95:34064 USPATFULL

TI Enhanced production of taxol and taxanes by cell **cultures** of taxus species

IN Bringi, Venkataraman, Ithaca, NY, United States
Kadkade, Prakash G., Marlboro, MA, United States
Prince, Christopher L., Ithaca, NY, United States
Schubmehl, Barry F., Ithaca, NY, United States
Kane, Eugene J., Ithaca, NY, United States
Roach, Braden, Interlaken, NY, United States

PA Phyton Catalytic, Inc., Ithaca, NY, United States (U.S. corporation)

PI US 5407816 19950418

AI US 1992-874344 19920424 (7)

RLI Continuation-in-part of Ser. No. US 1992-839144, filed on 20 Feb 1992, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Lilling, Herbert J.

LREP Baker, Hollie L.Hale and Dorr

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 14 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 1429

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 16 USPATFULL

AB Two chitinases from Trichoderma harzianum P1 (ATCC 74058) show chitin-containing-fungus-inhibiting activity. One is an endochitinase and the other is a chitobiase. Both have molecular weights of 40 kDa and isoelectric points of 3.9. Endochitinases and chitobiases including the two purified from Trichoderma harzianum strain P1 demonstrate synergy with each other in anti-fungal effect. Isolated gene encoding for the endochitinase has the sequence set forth in the Sequence Listing as SEQ ID NO:1.

AN 95:1723 USPATFULL

TI Gene encoding for endochitinase

IN Harman, Gary E., Geneva, NY, United States
Tronsmo, Arne, Aas, Norway
Hayes, Christopher K., Geneva, NY, United States
Lorito, Matteo, Salerno, Italy

PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)

PI US 5378821 19950103

AI US 1993-45269 19930414 (8)

RLI Continuation-in-part of Ser. No. US 1992-919784, filed on 27 Jul 1992 which is a continuation-in-part of Ser. No. US 1991-716134, filed on 17 Jun 1991, now patented, Pat. No. US 5173149

DT Utility

FS Granted

EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Pouty, Rebecca

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN 8 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 1279

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 16 USPATFULL

AB The invention relates to monoclonal antibodies that react specifically with members of the genus Leptosphaeria and hybridomas that produce such antibodies. The invention is further directed to a method for making a hybridoma cell line that produces monoclonal antibodies that react specifically with Leptosphaeria nodorum, and a method of obtaining monoclonal antibodies therefrom. Methods and kits for diagnosing Leptosphaeria infections in plant material using such monoclonal antibodies are also within the scope of the invention.

AN 93:46318 USPATFULL

TI Monoclonal antibodies to Leptosphaeria nodorum

IN Petersen, Frank P., Burlington, NJ, United States
Clymer, Mark D., Norristown, PA, United States
Miller, Sally A., Pennsauken, NJ, United States
Rittenburg, James H., Perkasie, PA, United States
Grothaus, G. David, Burlington, NJ, United States

PA Ciba-Geigy Corporation, Ardsley, NY, United States (U.S. corporation)

PI US 5217871 19930608

AI US 1990-570495 19900821 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Kepplinger, Esther L.; Assistant Examiner: Bidwell, Carol E.

LREP Foley, Shawn P.

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 907

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>